Mesoblast stock faces board refresh as two directors depart
Published on 11/06/2026 at 20:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSMesoblast prepares for commercial board phase
- William Burns plans to retire at Mesoblast's 2026 annual general meeting after 12 years on the board.
- Philip Krause has also left the board, while Jane Bell is taking over as chair of the Nomination and Remuneration Committee.
- Mesoblast plans to recruit directors with US and global commercial biopharmaceutical experience as Ryoncil sales expand.
Mesoblast is preparing a board refresh as the cell therapy company shifts its focus from development toward commercial delivery. Biotech Dispatch reported on November 3 that William Burns will retire at the 2026 annual general meeting and that Philip Krause will also leave the board.
Board changes mark commercial shift
Burns joined the board in 2014 and has served for 12 years. Jane Bell AM will take over as chair of the Nomination and Remuneration Committee, a role she had shared with Burns since April.
Krause, who joined the board in 2022 after a long career at the US Food and Drug Administration, contributed regulatory and clinical development expertise. Mesoblast credited him with helping advance Ryoncil to US Food and Drug Administration approval.
The company said it intends to recruit directors with US and global commercial experience in biotechnology and pharmaceuticals. It did not name candidates or provide a timetable. Chair Philip Facchina described Mesoblast as a revenue-generating commercial enterprise following Ryoncil's US launch.
Ryoncil remains the commercial anchor
Ryoncil is approved in the United States for steroid-refractory acute graft-versus-host disease in children aged two months and older. Mesoblast is also developing the therapy for additional inflammatory conditions, including adult steroid-refractory acute graft-versus-host disease and biologic-resistant inflammatory bowel disease.
The company is developing rexlemestrocel L for heart failure and chronic low back pain. Commercial partnerships cover Japan, Europe and China, giving the planned board additions a broader international remit.
The real-time quote of Mesoblast stock was 1.26 euros on Lang & Schwarz at 8:38:42 p.m. CET on Friday, November 6, 2026.
Mesoblast Limited at a glance
- ISIN: AU000000MSB8
- Trading symbol: MESO
- Lang & Schwarz quote: 1.26 euros on November 6, 2026 at 8:38:42 p.m. CET
- Ryoncil: FDA-approved for pediatric steroid-refractory acute graft-versus-host disease
Biotech Dispatch reported the board changes on November 3, 2026.
The Euro Stoxx 50 provides a broader market backdrop for European investors tracking biotechnology shares.
